455 related articles for article (PubMed ID: 36687468)
1. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
[TBL] [Abstract][Full Text] [Related]
2. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
[TBL] [Abstract][Full Text] [Related]
3. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
[TBL] [Abstract][Full Text] [Related]
4. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
Johnson K; Leary PJ; Govaere O; Barter MJ; Charlton SH; Cockell SJ; Tiniakos D; Zatorska M; Bedossa P; Brosnan MJ; Cobbold JF; Ekstedt M; Aithal GP; Clément K; Schattenberg JM; Boursier J; Ratziu V; Bugianesi E; Anstee QM; Daly AK; ;
JHEP Rep; 2022 Feb; 4(2):100409. PubMed ID: 35072021
[TBL] [Abstract][Full Text] [Related]
5. Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis.
Angelini G; Panunzi S; Castagneto-Gissey L; Pellicanò F; De Gaetano A; Pompili M; Riccardi L; Garcovich M; Raffaelli M; Ciccoritti L; Verrastro O; Russo MF; Vecchio FM; Casella G; Casella-Mariolo J; Papa L; Marini PL; Rubino F; le Roux CW; Bornstein S; Mingrone G
Gut; 2023 Feb; 72(2):392-403. PubMed ID: 35820779
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
Arora A; Sharma P
J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
[TBL] [Abstract][Full Text] [Related]
7. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
8. Secreted modular calcium-binding protein 2 promotes high fat diet (HFD)-induced hepatic steatosis through enhancing lipid deposition, fibrosis and inflammation via targeting TGF-β1.
Yuting Y; Lifeng F; Qiwei H
Biochem Biophys Res Commun; 2019 Jan; 509(1):48-55. PubMed ID: 30581002
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
10. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
Harrison SA; Ratziu V; Boursier J; Francque S; Bedossa P; Majd Z; Cordonnier G; Sudrik FB; Darteil R; Liebe R; Magnanensi J; Hajji Y; Brozek J; Roudot A; Staels B; Hum DW; Megnien SJ; Hosmane S; Dam N; Chaumat P; Hanf R; Anstee QM; Sanyal AJ
Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):970-985. PubMed ID: 32763196
[TBL] [Abstract][Full Text] [Related]
11. Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis.
Bhattacharya D; Basta B; Mato JM; Craig A; Fernández-Ramos D; Lopitz-Otsoa F; Tsvirkun D; Hayardeny L; Chandar V; Schwartz RE; Villanueva A; Friedman SL
JHEP Rep; 2021 Jun; 3(3):100237. PubMed ID: 34151243
[TBL] [Abstract][Full Text] [Related]
12. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
[TBL] [Abstract][Full Text] [Related]
13. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease.
Jiao J; Sanchez JI; Saldarriaga OA; Solis LM; Tweardy DJ; Maru DM; Stevenson HL; Beretta L
JHEP Rep; 2023 Feb; 5(2):100628. PubMed ID: 36687470
[TBL] [Abstract][Full Text] [Related]
14. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL
J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
[TBL] [Abstract][Full Text] [Related]
15. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ;
PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375
[TBL] [Abstract][Full Text] [Related]
16. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
17. Hepatic SPARC Expression Is Associated with Inflammasome Activation during the Progression of Non-Alcoholic Fatty Liver Disease in Both Mice and Morbidly Obese Patients.
Onorato AM; Lameroli Mauriz L; Bayo J; Fiore E; Cantero MJ; Bueloni B; García M; Lagües C; Martínez-Duartez P; Menaldi G; Paleari N; Atorrasagasti C; Mazzolini GD
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834291
[TBL] [Abstract][Full Text] [Related]
18. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
19. A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage.
Segal-Salto M; Barashi N; Katav A; Edelshtein V; Aharon A; Hashmueli S; George J; Maor Y; Pinzani M; Haberman D; Hall A; Friedman S; Mor A
JHEP Rep; 2020 Feb; 2(1):100064. PubMed ID: 32039405
[TBL] [Abstract][Full Text] [Related]
20. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
